Cake10
9月前
As I stated, how he opines is immaterial (despite the fact that he’s on record for liking the company, which is why he had Perry on twice and talked about liking the product many times thereafter). But that was a long time ago. Though positive sentiment never hurts, his “OPINEion” is largely immaterial in the scheme of the facts: FDA approvals, broadening scope, increasing sales, plenty of cash, halo product, and a path to profitability, to mention a few.
And, yes, he does do quite intensive research. He may be wacky, but he’s extremely thorough and highly intelligent. Both he and CNBC have extensive resources and staff that do serious due diligence. I assure you he will see what we ALL see. And he will like A LOT. Maybe all of it. But yes, in the final analysis, he may hedge because of the market cap. Or because they’re not yet profitable though that’s not an intransigent sentiment with him. He mainly holds that position in a risk-off environment with recessionary risk or looming rate hikes as we’ve been in the last couple years.
But these days are different. Have you seen Bitcoin lately? Upcoming IPOs? Anticipated rate cuts? We’re in a very different market than a few months ago and he may change his tune, especially when this company will be profitable by next year. Or he may not. Doesn’t really matter.
No — this is ALL about visibility. Institutions are very well aware of this stock with a couple having taken deep bites, but the retail investor by and a large? I don’t know. This stock is/was mostly held by retail last I checked, but that doesn’t necessarily indicate plurality. Many may have it off their radars these days. Many may just need a couple of positive comments that piques their interest and jives with their risk tolerance. This is who I would expect to come looking. Thousands will look. Some will buy. Maybe small fish. Maybe big fish. There’s no way to know. All I’m saying is “hold on tight.” TiGETTY-tight.
PS: relying “on the new executives executing what seems like a very workable strategy” is in no way shape or form mutually exclusive to gaining massive visibility. Both can be had.
Cake10
9月前
Mad Money episode tonight 2/29/24 … on Leap Day of all days.
Caller: Cramer what do you think about Avita Medical?
Cramer: I do not know this company! I will have to do some work.
First of all, the question surprised me. Second, I was surprised they allowed the call to go through as the show, I believe, requires a company to have a minimum market cap of $1B or $1.5B for it to be discussed. He had Mike Perry ON his show twice (once in person) around 2019 or 2020 during its huge run up toward all-time highs when it was around that market cap. He will definitely remember once his staff does their due diligence. This is a FAR more advanced company than it was then.
Usually (maybe always) he’ll do a follow-up with his “homework” updating viewers on questions about stocks on which he was stumped by callers.
This should be VERY interesting, not necessarily because of what he does/doesn’t have to say (you should rely on your own research), but for the mere fact that he has a massive audience and massive platform for visibility.
Hold on VERY tightly to your shares until if/that segment airs, potentially within the next few weeks.
believeinsteven
1年前
“We have achieved significant commercial revenue growth rates for
the last three quarters of 40%, 42% and 51%, respectively, over the
same periods in the previous year,” said David O’Toole, Chief
Financial Officer of AVITA Medical. “Further, we remain confident
that our cash reserves position us to achieve our goals and reach
profitability in 2025.”
Windbag1014
1年前
As previously disclosed, on June 30, 2023, AVITA Medical, Inc. (the
“Company”) submitted a premarket approval supplement application
(the “PMA”) to the U.S. Food and Drug Administration (the “FDA”)
for its latest device, RECELL GO™. The submission initiated a
prioritized, interactive review of the PMA under the FDA’s
Breakthrough Device program, which follows a 180-day review
cycle.
At the halfway point of the process, the Company received notice
from the FDA that additional information regarding the PMA is
required for the continuation of a substantive review. This
request, which is not unique to the Breakthrough Device Program,
places the application file on hold for approximately 4 to 6 months
while the Company addresses the FDA's questions. Upon the Company’s
submission of a complete response to the FDA’s request, the
application will reenter the 180-day cycle, with 90 days remaining
in the review period. This timing would imply a product launch
between May 1 and July 1, 2024.